ArticleMaterials today. Bio2026
Restoring disc matrix homeostasis: Dual-miRNA and human platelet lysate as a novel therapeutic strategy.
Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Biomaterials for intervertebral disc regeneration: Niche reprogramming, precision therapeutics, and structural reconstruction.Bioactive materials · 2027Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intervertebral disc (IVD) degeneration is the predominant cause of low back pain, resulting from progressive extracellular matrix (ECM) degradation and establishment of a pro-catabolic microenvironment. microRNA (miRNA) delivery has potential to promote ECM restoration and curb the catabolic milieu. We previously demonstrated a robust anti-catabolic effect through the delivery of a dual-miRNA injectable therapy in ex vivo organ culture models of degeneration. However, to further enhance regenerative outcomes, additional stimulation, such as supplementation with human platelet lysate (HPL) may strengthen this therapeutic strategy. Supplementation of rat nucleus pulposus (NP) cells with the dual-miRNA-FLR-149-5p mimic and miRNA-221-3p inhibitor and HPL was assessed in monolayer and ex vivo organ culture modelling mild degeneration. To evaluate the translatability of our approach, a tuneable patient NP cell-laden NP-ECM gel analogue was developed. For all models, key ECM constituents and matrix-degrading proteins were assessed biochemically, histologically, and using immunofluorescence. HPL supplementation combined with FLR-miRNA-149-5p and 221-3p inhibitor resulted in increased ECM regenerative proteins, SRY-box transcription factor 9 (SOX9), and aggrecan, while suppressing catabolic factors from matrix-degrading enzymes disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS) and matrix metalloproteinases (MMPs). Importantly, rat and human culture models were consistent in their response, highlighting the clinical translatability of our models and therapeutic strategy. Combined delivery of dual-miRNA with HPL delivery in rat and human models of mild degeneration enhanced expression of restorative ECM proteins while suppressing matrix-degrading factors. These findings highlight a novel and promising therapeutic strategy for the treatment of early-stage IVD degeneration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.